Literature DB >> 27600138

P-glycoprotein Function in the Rodent Brain Displays a Daily Rhythm, a Quantitative In Vivo PET Study.

Heli Savolainen1, Peter Meerlo2, Philip H Elsinga1, Albert D Windhorst3, Rudi A J O Dierckx1, Nicola A Colabufo4,5, Aren van Waarde1, Gert Luurtsema6.   

Abstract

The blood-brain barrier (BBB) contributes to brain homeostasis by protecting the brain from harmful compounds. P-glycoprotein (P-gp) is one of the major efflux transporters at the BBB. In the present study, we assessed whether (1) P-gp function in the brain is constant or fluctuates across the day and (2) if it is affected by sleep deprivation. Four groups of rats were PET scanned with a radiolabeled P-gp substrate [18F]MC225, each at a different moment of the 12-h light-dark cycle to study diurnal variations: early sleep phase (ZT3), late sleep phase (ZT9), early active phase (ZT15), and late active phase (ZT21). In two additional groups, controls were allowed to sleep normally while experimental animals were sleep-deprived for 10 h in a slowly rotating drum during the sleep phase. Kinetic modeling with a one-tissue compartment model fit resulted for all brain regions in 1.2-1.8-fold higher distribution volumes (V T ) at ZT15 than at other time points. V T -values at ZT3, ZT9, and ZT21 were not significantly different from each other. Regional tracer distribution volumes in controls and sleep-deprived animals were also not significantly different. Our results indicate that P-gp function in rats displays a daily rhythm with reduced function at the beginning of the active phase. This rhythm is not dependent on sleep since acute sleep deprivation had no effect. Knowing the diurnal variation of P-gp function could be important for the design of PET studies and for choosing the correct administration time for P-gp-dependent drugs.

Entities:  

Keywords:  [18F]MC225; circadian rhythm; efflux transporter; pharmacokinetic modeling; sleep deprivation

Mesh:

Substances:

Year:  2016        PMID: 27600138     DOI: 10.1208/s12248-016-9973-3

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  40 in total

Review 1.  Cardiovascular disease, chronopharmacotherapy, and the molecular clock.

Authors:  Norihiko Takeda; Koji Maemura
Journal:  Adv Drug Deliv Rev       Date:  2010-05-06       Impact factor: 15.470

Review 2.  Circadian control of the sleep-wake cycle.

Authors:  Domien G M Beersma; Marijke C M Gordijn
Journal:  Physiol Behav       Date:  2006-10-18

3.  Evaluation of [18F]MC225 as a PET radiotracer for measuring P-glycoprotein function at the blood-brain barrier in rats: Kinetics, metabolism, and selectivity.

Authors:  Heli Savolainen; Albert D Windhorst; Philip H Elsinga; Mariangela Cantore; Nicola A Colabufo; Antoon Tm Willemsen; Gert Luurtsema
Journal:  J Cereb Blood Flow Metab       Date:  2016-01-01       Impact factor: 6.200

Review 4.  Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy.

Authors:  David S Miller; Björn Bauer; Anika M S Hartz
Journal:  Pharmacol Rev       Date:  2008-06-17       Impact factor: 25.468

5.  Circadian clock and cancer therapy: an unexpected journey.

Authors:  Roman Kondratov
Journal:  Ann Med       Date:  2014-06       Impact factor: 4.709

6.  Daily rhythms of P-glycoprotein expression in mice.

Authors:  Hitoshi Ando; Hayato Yanagihara; Koh-ichi Sugimoto; Yohei Hayashi; Shuichi Tsuruoka; Toshinari Takamura; Shuichi Kaneko; Akio Fujimura
Journal:  Chronobiol Int       Date:  2005       Impact factor: 2.877

Review 7.  Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs.

Authors:  Pauline Breedveld; Jos H Beijnen; Jan H M Schellens
Journal:  Trends Pharmacol Sci       Date:  2005-12-05       Impact factor: 14.819

Review 8.  Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings.

Authors:  Fionn E O'Brien; Timothy G Dinan; Brendan T Griffin; John F Cryan
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

9.  Induction of P-glycoprotein and Bcrp at the rat blood-brain barrier following a subchronic morphine treatment is mediated through NMDA/COX-2 activation.

Authors:  Salah Yousif; Catarina Chaves; Sophie Potin; Isabelle Margaill; Jean-Michel Scherrmann; Xavier Declèves
Journal:  J Neurochem       Date:  2012-09-03       Impact factor: 5.372

10.  Comparative description of haplotype structure and genetic diversity of MDR1 (ABCB1) in HIV-positive and HIV-negative populations.

Authors:  Rebekah L Benish; Benigno Rodriguez; Peter A Zimmerman; Rajeev K Mehlotra
Journal:  Infect Genet Evol       Date:  2009-10-09       Impact factor: 3.342

View more
  8 in total

Review 1.  Timing in drug absorption and disposition: The past, present, and future of chronopharmacokinetics.

Authors:  Joana Bicker; Gilberto Alves; Amílcar Falcão; Ana Fortuna
Journal:  Br J Pharmacol       Date:  2020-03-20       Impact factor: 8.739

Review 2.  Regulation of the Blood-Brain Barrier by Circadian Rhythms and Sleep.

Authors:  Vishnu Anand Cuddapah; Shirley L Zhang; Amita Sehgal
Journal:  Trends Neurosci       Date:  2019-07       Impact factor: 13.837

3.  Neuronal Activity Regulates Blood-Brain Barrier Efflux Transport through Endothelial Circadian Genes.

Authors:  Robert S Pulido; Roeben N Munji; Tamara C Chan; Clare R Quirk; Geoffrey A Weiner; Benjamin D Weger; Meghan J Rossi; Sara Elmsaouri; Mario Malfavon; Aaron Deng; Caterina P Profaci; Marie Blanchette; Tongcheng Qian; Koji L Foreman; Eric V Shusta; Michael R Gorman; Frédéric Gachon; Stefan Leutgeb; Richard Daneman
Journal:  Neuron       Date:  2020-09-25       Impact factor: 17.173

Review 4.  Molecular Aspects of Circadian Pharmacology and Relevance for Cancer Chronotherapy.

Authors:  Narin Ozturk; Dilek Ozturk; Ibrahim Halil Kavakli; Alper Okyar
Journal:  Int J Mol Sci       Date:  2017-10-17       Impact factor: 5.923

5.  Comparison of In Vitro Assays in Selecting Radiotracers for In Vivo P-Glycoprotein PET Imaging.

Authors:  Renske M Raaphorst; Heli Savolainen; Mariangela Cantore; Evita van de Steeg; Aren van Waarde; Nicola A Colabufo; Philip H Elsinga; Adriaan A Lammertsma; Albert D Windhorst; Gert Luurtsema
Journal:  Pharmaceuticals (Basel)       Date:  2017-09-20

6.  First clinical assessment of [18F]MC225, a novel fluorine-18 labelled PET tracer for measuring functional P-glycoprotein at the blood-brain barrier.

Authors:  Jun Toyohara; Muneyuki Sakata; Kenji Ishibashi; Pascalle Mossel; Masamichi Imai; Kei Wagatsuma; Tetsuro Tago; Etsuko Imabayashi; Nicola A Colabufo; Gert Luurtsema; Kenji Ishii
Journal:  Ann Nucl Med       Date:  2021-08-08       Impact factor: 2.668

7.  The blood-brain barrier in health and disease: Important unanswered questions.

Authors:  Caterina P Profaci; Roeben N Munji; Robert S Pulido; Richard Daneman
Journal:  J Exp Med       Date:  2020-04-06       Impact factor: 14.307

8.  Circadian Influences on Chemotherapy Efficacy in a Mouse Model of Brain Metastases of Breast Cancer.

Authors:  William H Walker; Samuel A Sprowls; Jacob R Bumgarner; Jennifer A Liu; O Hecmarie Meléndez-Fernández; James C Walton; Paul R Lockman; A Courtney DeVries; Randy J Nelson
Journal:  Front Oncol       Date:  2021-12-09       Impact factor: 5.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.